GLEN ALLEN, Va., Sept. 10, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary Rock Creek Pharmaceuticals, Inc. announced today that the Company’s new Anatabloc® face cream is now available on the cosmetic portion of the Anatabloc® website (www.anatabloc.com) and in select dermatology practices.
(Photo: http://photos.prnewswire.com/prnh/20120910/PH70858 )
(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )
Star Scientific and Rock Creek Pharmaceuticals have been developing this new face cream for more than two years. The product is a unique formulation of anatabine citrate and a botanically-based emollient. (Anatabine citrate is one of the active ingredients in the Company’s successful Anatabloc® nutritional supplement.) The Anatabloc® face cream has been demonstrated to considerably improve the appearance of the skin in a broad variety of volunteers and in a case series conducted by leading dermatologist Dr. Susan H. Weinkle of Bradenton, Florida, President of the American Society for Dermatologic Surgery and Assistant Clinical Professor of Dermatology at the University of South Florida.
Dr. Weinkle stated, “My dermatology colleagues and I are very excited about the new Anatabloc® face cream. In my opinion, it represents a genuine breakthrough in improving the appearance of the skin, especially in difficult cases. I selected patients who had significant needs and who had not responded to other cosmetic creams. It clearly worked where other creams had failed, and we have initiated further study to define where it may be of greatest benefit.”
Dr. Marina Landau, a prominent medical and cosmetic dermatologist in Israel who is Immediate Past President of the Israeli Society for Dermatologic Surgery and a member of the board of directors of the International Society for Dermatologic Surgery, commented, “I had a patient who had significant redness after a surgical peel. I was astounded by the improvement in the appearance of the skin after she used the Anatabloc® cream for just a short amount of time. It was a surprise and like nothing I have ever seen. The improvement in the appearance of the skin was prompt, significant, and very gratifying to the patient. I really look forward to working with this product.”
Paul L. Perito, Rock Creek’s Chairman and CEO, stated, “I have been following the development of our cosmetic cream formulation with considerable excitement. Our mission to use botanically based products to promote a healthy lifestyle has been enhanced by the addition of this line extension, Anatabloc® face cream.”
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA; Executive, Scientific & Regulatory Affairs offices in Bethesda, MD, and Washington, DC; and a manufacturing facility in Chase City, VA.
Contact:
Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.
(301) 654-8300
ttuck@starscientific.com
SOURCE Star Scientific, Inc.
